- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07918261
Evaluation of Fisetin to Reduce Systemic Senescence
Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study
This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Colorado
-
Vail, Colorado, Estados Unidos, 81657
- Steadman Philippon Research Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults ≥55 years of age;
- Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
- Willing to comply with all study procedures and assessments.
Exclusion Criteria:
-
Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);
-
Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;
-
Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;
-
Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;
-
Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;
-
Subjects with any of the following drug/medication statuses:
- Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
- Currently taking Warfarin or related anticoagulants;
- Currently taking Lithium;
- Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
- Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
- Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
- Taking a glucocorticoid within 1 month of signing informed consent;
- Currently taking phenytoin or nateglinide;
-
PHQ-9 - Patient Health Questionnaire - total score exceeds 9;
-
Inability to tolerate oral medication;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Fisetin (daily dosing)
A single Fisetin 100mg capsule will be taken daily for 60 days. |
Oral Fisetin 100mg capsule
Otros nombres:
|
|
Experimental: Fisetin (bolus dosing)
Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32. |
Oral Fisetin 100mg capsule, dosed at 20 mg/kg
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Periodo de tiempo: Baseline, Visit 4 (45 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 4 (45 days)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Periodo de tiempo: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
|
Change from baseline in senescence-related serum biomarkers
Periodo de tiempo: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Number of participants experiencing one or more treatment-emergent adverse events
Periodo de tiempo: From date of study drug dosing until the end of the study, an average of 2 months
|
Number of participants experiencing one or more treatment-emergent adverse events |
From date of study drug dosing until the end of the study, an average of 2 months
|
|
Perturbations in senescent PBMC values
Periodo de tiempo: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Perturbations in senescent serum/plasma biomarkers values
Periodo de tiempo: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Johnny Huard, PhD, Steadman Philippon Research Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2022-154
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .